NovaBridge subsidiary Visara doses first patient in Phase 2b trial of VIS-101 for wet AMD
NBP•NovaBridge Biosciences' majority-owned subsidiary Visara dosed the first patient in its approximately 244-patient ASCEND Phase 2b trial of VIS-101 for wet AMD in China.
1. Trial begins
Conducted with Everest Medicines, ASCEND compares 6 mg and 9 mg doses of VIS-101 with 2 mg aflibercept administered every eight weeks. After monthly loading doses, VIS-101 treatment intervals could reach seven months; results will guide dose selection for global Phase 3 trials. In Phase 2a, approximately 50% of treatment-naive patients who received 6 mg remained retreatment-free six months after their last loading dose.




